ClinicalTrials.gg
Active, not recruitingNCT04182776Updated Jul 13, 2026

Fragility Fractures of the Pelvis (FFP)

An observational study in Pelvic Fracture, sponsored by AO Innovation Translation Center. Active, not recruiting at 10 sites in 7 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by AO Innovation Translation Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
420
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Hip Fractures with a site in Germany — 1 open to participants now, 9 under way, none of them phase 3. Hip Fractures · Germany.

Started
2022
the only one that year
Observational
9 of 25
none open now
Registered
18th of 25
by date
Lead sponsor
3 of 25
AO Innovation Translation Center

Among the 25 studies in Hip Fractures with a site in Germany, this one is the only one that started in 2022, is one of 9 observational ones, and was the 18th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

1 of the 25 studies in Hip Fractures with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hip Fractures with a site in Germany, or all of them as a file.
02

Study summary

Prospective data will be collected in approximately 420 patients, above the age of 65, suffering from an FFP type fracture equal to or higher than type II, according to Rommens and Hofmann.

Patients will be followed up according to the standard (routine) for up to 1 year after the treatment. Data collection will include underlying disease, treatment details, functional and patient reported outcomes (PRO)s, radiological outcomes, and anticipated or procedure-related adverse events (i.e. complications).

Read the detailed description

More in detail this registry has the following objectives:

  • To identify the difference in patient related outcome comparing the surgical and conservative treatment in patients suffering from an FFP with different levels of pelvic instability at different time points
  • To compare the rate of complications, morbidity and mortality between the different treatment modalities over the whole study period
03

Conditions studied

  • Pelvic Fracture

Browse trials for

Keywords

  • Pelvis
  • Fragility Fracture
  • Classification
  • Conservative
  • Operative
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Elderly patients (over 65) who have suffered from fragility fractures of the pelvis (FFP), equal to or higher than type II (according to Rommens and Hofmann)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years or older at time of injury
  • Diagnosis, via CT scan as per standard of care, of FFP grade II or higher according to the Rommens and Hofmann classification (including fractures of the anterior pelvic ring involving the anterior lip of the acetabulum not regarded as the acetabular fractures)
  • obtained, ie:

    • Ability to understand the content of the patient information/ICF
    • Willingness and ability to participate in the registry according to the standard of care in each clinic
    • Signed and dated Ethics Committee (EC)/ Institutional Review Board (IRB) approved written informed consent OR
    • Written consent provided according to the IRB/EC defined and approved procedures for patients who are not able to provide independent written informed consent

Exclusion criteria

Exclusion Criteria:

  • Pelvic fractures that do not meet the criteria of a fragility fracture (ie, high-energy trauma)
  • FFP type I fractures
  • Concomitant fractures of the acetabulum (except anterior lip of the acetabulum, see above)
  • Pathological fractures (ie, patients with malignant or diseases of the pelvis, infections)
  • Concomitant osteoporotic fractures outside of pelvis
  • Participation in any other medical device or medicinal product study within the previous month that could influence in opinion of the PI the results of the present registry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
420 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Pelvis fracture type II to IV

    All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.

06

What researchers measure

Primary outcomes

  1. Demographics

    Year of birth, Gender, Ethnicity, Height (cm) and Weight (kg) will be combined to report BMI in kg/m\^2

    Time frame: Pre-treatment

  2. Comorbidities

    Concomitant diseases will be assessed using the Charlson Comorbidity Index (CCI). This score assesses the comorbidity level by considering both the number and severity of pre-defined comorbid conditions. It provides a weighted score of a patient's comorbidities which can be used to predict mortality rates. It is a 17-items questionnaire with score range from 0 to 37 points. It estimates the 10-year (or shorter) patient survival.

    Time frame: Pre-treatment

  3. Cognitive status

    The MiniCog is a 3-minute instrument assessing cognitive impairment. It consists of two components, a 3-item recall test for memory and a simply scored clock drawing test. A total score ranges from 0 to 5. A score of zero, one or two out of five points in total, indicates a concern in cognitive functioning.

    Time frame: Pre-treatment

  4. Patient-reported outcomes: PROMIS Pain Interference

    PROMIS (Patient-Reported Outcome Measurement Information System) Pain Interference (8 questions) assesses the impact of pain on common activities of daily life including social, cognitive, emotional, physical, and recreational aspects. The higher score represents a higher pain level.

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

  5. Patient-reported outcomes: PROMIS Physical Function

    PROMIS Physical Function (10 questions) assesses self-reported capability of physical activities including instrumental activities of daily living. A higher score indicates a better self-reported capability.

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

  6. Patient Reported Outcomes - EuroQoL (EQ-5D-3L)

    The EQ-5D-3L has five items (mobility, self-care, usual activities, pain/discomfort anxiety/depression) with a three-point categorical response scale level (1 = no problems, 2 = some / moderate problems, 3 = extreme problems) where the patient's current health status is assessed. A unique EQ-5D-3L health state is defined by combining one level from each of the five dimensions. The EQ-5D index score ranges from 0 (death) to 1 (best imaginable quality of life), and negative values express "worse than death" state.

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

Secondary outcomes

  1. Parker Mobility Score

    Parker Mobility Scale assess the patient's ability to perform indoor walking, outdoor walking, and shopping before the fracture. A score ranges between 0 and 3 (0 = not at all, 1 = with help from another person, 2 = with an aid, and 3 = no difficulty and no aid) for each function, resulting in a total score ranging from 0 (no walking ability at all) to 9 (fully independent).

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

  2. Modified Barthel index

    The Barthel index is an ordinal scale and each performance item is rated on this scale with a given number of points assigned to each level or ranking. It uses 10 variables describing activities of daily living and mobility. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

  3. Residential status

    The residential status will be documented at each visit during 1-year post-treatment phase.

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

  4. Mortality

    Mortality will be assessed for 4 phases: * Perioperative mortality * Within the first 7 days after treatment (early-term) * Within the first 3 months after treatment (mid-term) * Until the last follow up (long-term mortality)

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

  5. Radiological outcomes

    Position of the fracture fragments, to rule out secondary (additional) fracture fragments and displacement, or loosening of implants (Undisplaced, Displaced, Non-union with extensive callus)

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

  6. Anticipated treatment or condition-related adverse events (i.e. complications)

    In this registry, only condition- or treatment-related events (ie complications) will be collected . Partially those events presuppose themselves: eg, re-admission for a surgical revision. In those cases, details on those different events will be collected.

    Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)

07

Study locations

10 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2027, 64 months after the start.

Of 107 non-industry observational studies under Hip Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 65. This study's planned 64 months is above that.

Counting every sponsor, half of 124 studies reached it within 28 months; a quarter within 12 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Dec 2, 2019
StartActual
Mar 1, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04182776
Lead sponsor
AO Innovation Translation Center
Responsible party
Sponsor
First posted
Dec 2, 2019
Start date
Mar 1, 2022
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Pol Maria Rommens, MD
principal investigator · University Medical Center Johannes Gutenberg-University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion